Skip to main content
Top
Published in: Drugs & Aging 6/2016

01-06-2016 | Original Research Article

Associations Between Statin Use and Physical Function in Older Adults from The Netherlands and Australia: Longitudinal Aging Study Amsterdam and Australian Longitudinal Study on Women’s Health

Published in: Drugs & Aging | Issue 6/2016

Login to get access

Abstract

Background

Statin therapy may cause myopathy, but long-term effects on physical function are unclear.

Objective

We investigated whether statin use is associated with poorer physical function in two population-based cohorts of older adults.

Methods

Data were from 691 men and women (aged 69–102 years in 2005/2006) in the LASA (Longitudinal Aging Study Amsterdam) and 5912 women (aged 79–84 years in 2005) in the ALSWH (Australian Longitudinal Study on Women’s Health). Statin use and dose were sourced from containers (LASA) and administrative databases (ALSWH). Physical function was assessed using performance tests, questionnaires on functional limitations and the SF-12 (LASA) and SF-36 (ALSWH) questionnaires. Cross-sectional (both studies) and 3-year prospective associations (ALSWH) were analysed for different statin dosage using linear and logistic regression.

Results

In total, 25 % of participants in LASA and 61 % in ALSWH used statins. In the cross-sectional models in LASA, statin users were less likely to have functional limitations (percentage of subjects with at least 1 limitation 63.9 vs. 64.2; odds ratio [OR] 0.6; 95 % confidence interval [CI] 0.3–0.9) and had better SF-12 physical component scores (mean [adjusted] 47.3 vs. 44.5; beta [B] = 2.8; 95 % CI 1.1–4.5); in ALSWH, statin users had better SF-36 physical component scores (mean [adjusted] 37.4 vs. 36.5; B = 0.9; 95 % CI 0.3–1.5) and physical functioning subscale scores (mean [adjusted] 55.1 vs. 52.6; B = 2.4; 95 % CI 1.1–3.8) than non-users. Similar associations were found for low- and high-dose users and in the prospective models. In contrast, no significant associations were found with performance tests.

Conclusions

Two databases from longitudinal population studies in older adults gave comparable results, even though different outcome measures were used. In these two large cohorts, statin use was associated with better self-perceived physical function.
Appendix
Available only for authorised users
Literature
1.
go back to reference Geleedst-De VM, Maitland-van der Zee AH, Schalekamp T, Mantel-Teeuwisse A, Jansen P. Statin prescribing in the elderly in The Netherlands: a pharmacy database time trend study. Drugs Aging. 2010;27(7):589–96.CrossRef Geleedst-De VM, Maitland-van der Zee AH, Schalekamp T, Mantel-Teeuwisse A, Jansen P. Statin prescribing in the elderly in The Netherlands: a pharmacy database time trend study. Drugs Aging. 2010;27(7):589–96.CrossRef
2.
go back to reference Peeters G, Tett SE, Conaghan PG, Mishra GD, Dobson AJ. Is statin use associated with new joint-related symptoms, physical function and quality of life? The Australian Longitudinal Study on Women’s Health. Arthritis Care Res (Hoboken). 2015;67(1):13–20.CrossRefPubMed Peeters G, Tett SE, Conaghan PG, Mishra GD, Dobson AJ. Is statin use associated with new joint-related symptoms, physical function and quality of life? The Australian Longitudinal Study on Women’s Health. Arthritis Care Res (Hoboken). 2015;67(1):13–20.CrossRefPubMed
3.
go back to reference Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267–78.CrossRefPubMed Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267–78.CrossRefPubMed
4.
go back to reference Bruckert E, Hayem G, Dejager S, Yau C, Begaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients–the PRIMO study. CardiovascDrugs Ther. 2005;19(6):403–14.CrossRef Bruckert E, Hayem G, Dejager S, Yau C, Begaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients–the PRIMO study. CardiovascDrugs Ther. 2005;19(6):403–14.CrossRef
6.
go back to reference Tomlinson SS, Mangione KK. Potential adverse effects of statins on muscle. Phys Ther. 2005;85(5):459–65.PubMed Tomlinson SS, Mangione KK. Potential adverse effects of statins on muscle. Phys Ther. 2005;85(5):459–65.PubMed
7.
go back to reference Pasternak RC, Smith SC Jr, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Circulation. 2002;106(8):1024–8.CrossRefPubMed Pasternak RC, Smith SC Jr, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Circulation. 2002;106(8):1024–8.CrossRefPubMed
8.
go back to reference Haerer W, Delbaere K, Bartlett H, Lord SR, Rowland J. Relationships between HMG-CoA reductase inhibitors (statin) use and strength, balance and falls in older people. Intern Med J. 2012;42(12):1329–34.CrossRefPubMed Haerer W, Delbaere K, Bartlett H, Lord SR, Rowland J. Relationships between HMG-CoA reductase inhibitors (statin) use and strength, balance and falls in older people. Intern Med J. 2012;42(12):1329–34.CrossRefPubMed
9.
go back to reference Corsonello A, Garasto S, Abbatecola AM, Rose G, Passarino G, Mazzei B, et al. Targeting inflammation to slow or delay functional decline: where are we? Biogerontology. 2010;11(5):603–14.CrossRefPubMed Corsonello A, Garasto S, Abbatecola AM, Rose G, Passarino G, Mazzei B, et al. Targeting inflammation to slow or delay functional decline: where are we? Biogerontology. 2010;11(5):603–14.CrossRefPubMed
10.
go back to reference Cham S, Evans MA, Denenberg JO, Golomb BA. Statin-associated muscle-related adverse effects: a case series of 354 patients. Pharmacotherapy. 2010;30(6):541–53.CrossRefPubMedPubMedCentral Cham S, Evans MA, Denenberg JO, Golomb BA. Statin-associated muscle-related adverse effects: a case series of 354 patients. Pharmacotherapy. 2010;30(6):541–53.CrossRefPubMedPubMedCentral
11.
go back to reference Huisman M, Poppelaars J, van der Horst M, Beekman AT, Brug J, van Tilburg TG, et al. Cohort profile: the Longitudinal Aging Study Amsterdam. Int J Epidemiol. 2011;40(4):868–76.CrossRefPubMed Huisman M, Poppelaars J, van der Horst M, Beekman AT, Brug J, van Tilburg TG, et al. Cohort profile: the Longitudinal Aging Study Amsterdam. Int J Epidemiol. 2011;40(4):868–76.CrossRefPubMed
12.
go back to reference Lee C, Dobson AJ, Brown WJ, Bryson L, Byles J, Warner-Smith P, et al. Cohort Profile: the Australian Longitudinal Study on Women’s Health. Int J Epidemiol. 2005;34(5):987–91.CrossRefPubMed Lee C, Dobson AJ, Brown WJ, Bryson L, Byles J, Warner-Smith P, et al. Cohort Profile: the Australian Longitudinal Study on Women’s Health. Int J Epidemiol. 2005;34(5):987–91.CrossRefPubMed
13.
go back to reference Guralnik JM, Simonsick EM, Ferrucci L, Glynn RJ, Berkman LF, Blazer DG, Scherr PA, Wallace RB. A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission. J Gerontol. 1994;49(2):M85–94.CrossRefPubMed Guralnik JM, Simonsick EM, Ferrucci L, Glynn RJ, Berkman LF, Blazer DG, Scherr PA, Wallace RB. A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission. J Gerontol. 1994;49(2):M85–94.CrossRefPubMed
14.
go back to reference Gandek B, Ware JE, Aaronson NK, Apolone G, Bjorner JB, Brazier JE, et al. Cross-validation of item selection and scoring for the SF-12 Health Survey in nine countries: results from the IQOLA Project. International Quality of Life Assessment. J Clin Epidemiol. 1998;51(11):1171–8.CrossRefPubMed Gandek B, Ware JE, Aaronson NK, Apolone G, Bjorner JB, Brazier JE, et al. Cross-validation of item selection and scoring for the SF-12 Health Survey in nine countries: results from the IQOLA Project. International Quality of Life Assessment. J Clin Epidemiol. 1998;51(11):1171–8.CrossRefPubMed
15.
go back to reference McCallum J. The SF-36 in an Australian sample: validating a new, generic health status measure. Aust J Public Health. 1995;19(2):160–6.CrossRefPubMed McCallum J. The SF-36 in an Australian sample: validating a new, generic health status measure. Aust J Public Health. 1995;19(2):160–6.CrossRefPubMed
18.
go back to reference Bakhai A, Rigney U, Hollis S, Emmas C. Co-administration of statins with cytochrome P450 3A4 inhibitors in a UK primary care population. Pharmacoepidemiol Drug Saf. 2012;21(5):485–93.CrossRefPubMed Bakhai A, Rigney U, Hollis S, Emmas C. Co-administration of statins with cytochrome P450 3A4 inhibitors in a UK primary care population. Pharmacoepidemiol Drug Saf. 2012;21(5):485–93.CrossRefPubMed
19.
go back to reference Bongers IM, van Oers HA, van de Goor IA, Garretsen HF. Alcohol use and problem drinking: prevalences in the general Rotterdam population. Subst Use Misuse. 1997;32(11):1491–512.CrossRefPubMed Bongers IM, van Oers HA, van de Goor IA, Garretsen HF. Alcohol use and problem drinking: prevalences in the general Rotterdam population. Subst Use Misuse. 1997;32(11):1491–512.CrossRefPubMed
20.
go back to reference Australian alcohol guidelines; health risks and benefits. National Health and Medical Research Council; 2001. Australian alcohol guidelines; health risks and benefits. National Health and Medical Research Council; 2001.
21.
go back to reference Stel VS, Smit JH, Pluijm SM, Visser M, Deeg DJ, Lips P. Comparison of the LASA Physical Activity Questionnaire with a 7-day diary and pedometer. J Clin Epidemiol. 2004;57(3):252–8.CrossRefPubMed Stel VS, Smit JH, Pluijm SM, Visser M, Deeg DJ, Lips P. Comparison of the LASA Physical Activity Questionnaire with a 7-day diary and pedometer. J Clin Epidemiol. 2004;57(3):252–8.CrossRefPubMed
22.
go back to reference Brown WJ, Burton NW, Marshall AL, Miller YD. Reliability and validity of a modified self-administered version of the Active Australia physical activity survey in a sample of mid-age women. Aust NZ J Public Health. 2008;32(6):535–41.CrossRef Brown WJ, Burton NW, Marshall AL, Miller YD. Reliability and validity of a modified self-administered version of the Active Australia physical activity survey in a sample of mid-age women. Aust NZ J Public Health. 2008;32(6):535–41.CrossRef
23.
go back to reference Scott D, Blizzard L, Fell J, Jones G. Statin therapy, muscle function and falls risk in community-dwelling older adults. QJM. 2009;102(9):625–33.CrossRefPubMed Scott D, Blizzard L, Fell J, Jones G. Statin therapy, muscle function and falls risk in community-dwelling older adults. QJM. 2009;102(9):625–33.CrossRefPubMed
24.
go back to reference Ashfield TA, Syddall HE, Martin HJ, Dennison EM, Cooper C, Aihie SA. Grip strength and cardiovascular drug use in older people: findings from the Hertfordshire Cohort Study. Age Ageing. 2010;39(2):185–91.CrossRefPubMedPubMedCentral Ashfield TA, Syddall HE, Martin HJ, Dennison EM, Cooper C, Aihie SA. Grip strength and cardiovascular drug use in older people: findings from the Hertfordshire Cohort Study. Age Ageing. 2010;39(2):185–91.CrossRefPubMedPubMedCentral
25.
go back to reference Witham MD, Syddall HE, Dennison E, Cooper C, McMurdo ME, Sayer AA. ACE inhibitors, statins and thiazides: no association with change in grip strength among community dwelling older men and women from the Hertfordshire Cohort Study. Age Ageing. 2014;43(5):661–6.CrossRefPubMed Witham MD, Syddall HE, Dennison E, Cooper C, McMurdo ME, Sayer AA. ACE inhibitors, statins and thiazides: no association with change in grip strength among community dwelling older men and women from the Hertfordshire Cohort Study. Age Ageing. 2014;43(5):661–6.CrossRefPubMed
26.
go back to reference Parker BA, Capizzi JA, Grimaldi AS, Clarkson PM, Cole SM, Keadle J, et al. Effect of statins on skeletal muscle function. Circulation. 2013;127(1):96–103.CrossRefPubMedPubMedCentral Parker BA, Capizzi JA, Grimaldi AS, Clarkson PM, Cole SM, Keadle J, et al. Effect of statins on skeletal muscle function. Circulation. 2013;127(1):96–103.CrossRefPubMedPubMedCentral
27.
go back to reference Panza GA, Taylor BA, Dada MR, Thompson PD. Changes in muscle strength in individuals with statin-induced myopathy: a summary of 3 investigations. J Clin Lipidol. 2015;9(3):351–6.CrossRefPubMed Panza GA, Taylor BA, Dada MR, Thompson PD. Changes in muscle strength in individuals with statin-induced myopathy: a summary of 3 investigations. J Clin Lipidol. 2015;9(3):351–6.CrossRefPubMed
28.
go back to reference Gray SL, Aragaki AK, LaMonte MJ, Cochrane BB, Kooperberg C, Robinson JG, et al. Statins, angiotensin-converting enzyme inhibitors, and physical performance in older women. J Am Geriatr Soc. 2012;60(12):2206–14.CrossRefPubMedPubMedCentral Gray SL, Aragaki AK, LaMonte MJ, Cochrane BB, Kooperberg C, Robinson JG, et al. Statins, angiotensin-converting enzyme inhibitors, and physical performance in older women. J Am Geriatr Soc. 2012;60(12):2206–14.CrossRefPubMedPubMedCentral
29.
go back to reference Lo-Ciganic WH, Perera S, Gray SL, Boudreau RM, Zgibor JC, Strotmeyer ES, Donohue JM, Bunker CH, Newman AB, Simonsick EM, Bauer DC, Satterfield S, Caserotti P, Harris T, Shorr RI, Hanlon JT, Health, Aging and Body Composition Study. Statin use and decline in gait speed in community-dwelling older adults. J Am Geriatr Soc. 2014;63(1):124–9. doi:10.1111/jgs.13134.CrossRefPubMedPubMedCentral Lo-Ciganic WH, Perera S, Gray SL, Boudreau RM, Zgibor JC, Strotmeyer ES, Donohue JM, Bunker CH, Newman AB, Simonsick EM, Bauer DC, Satterfield S, Caserotti P, Harris T, Shorr RI, Hanlon JT, Health, Aging and Body Composition Study. Statin use and decline in gait speed in community-dwelling older adults. J Am Geriatr Soc. 2014;63(1):124–9. doi:10.​1111/​jgs.​13134.CrossRefPubMedPubMedCentral
30.
go back to reference Agostini JV, Tinetti ME, Han L, McAvay G, Foody JM, Concato J. Effects of statin use on muscle strength, cognition, and depressive symptoms in older adults. J Am Geriatr Soc. 2007;55(3):420–5.CrossRefPubMed Agostini JV, Tinetti ME, Han L, McAvay G, Foody JM, Concato J. Effects of statin use on muscle strength, cognition, and depressive symptoms in older adults. J Am Geriatr Soc. 2007;55(3):420–5.CrossRefPubMed
31.
go back to reference Galindo-Ocana J, Bernabeu-Wittel M, Formiga F, Fuertes-Martin A, Baron-Franco B, Murcia-Zaragoza JM, et al. Effects of renin-angiotensin blockers/inhibitors and statins on mortality and functional impairment in polypathological patients. Eur J Intern Med. 2012;23(2):179–84.CrossRefPubMed Galindo-Ocana J, Bernabeu-Wittel M, Formiga F, Fuertes-Martin A, Baron-Franco B, Murcia-Zaragoza JM, et al. Effects of renin-angiotensin blockers/inhibitors and statins on mortality and functional impairment in polypathological patients. Eur J Intern Med. 2012;23(2):179–84.CrossRefPubMed
32.
go back to reference Dumurgier J, Singh-Manoux A, Tavernier B, Tzourio C, Elbaz A. Lipid-lowering drugs associated with slower motor decline in the elderly adults. J Gerontol A Biol Sci Med Sci. 2014;69(2):199–206.CrossRefPubMed Dumurgier J, Singh-Manoux A, Tavernier B, Tzourio C, Elbaz A. Lipid-lowering drugs associated with slower motor decline in the elderly adults. J Gerontol A Biol Sci Med Sci. 2014;69(2):199–206.CrossRefPubMed
33.
go back to reference Lo-Ciganic WH, Perera S, Gray SL, Boudreau RM, Zgibor JC, Strotmeyer ES, et al. Statin use and decline in gait speed in community-dwelling older adults. J Am Geriatr Soc. 2015;63(1):124–9.CrossRefPubMedPubMedCentral Lo-Ciganic WH, Perera S, Gray SL, Boudreau RM, Zgibor JC, Strotmeyer ES, et al. Statin use and decline in gait speed in community-dwelling older adults. J Am Geriatr Soc. 2015;63(1):124–9.CrossRefPubMedPubMedCentral
34.
go back to reference Cesari M, Penninx BW, Pahor M, Lauretani F, Corsi AM, Rhys WG, et al. Inflammatory markers and physical performance in older persons: the InCHIANTI study. J Gerontol A Biol Sci Med Sci. 2004;59(3):242–8.CrossRefPubMed Cesari M, Penninx BW, Pahor M, Lauretani F, Corsi AM, Rhys WG, et al. Inflammatory markers and physical performance in older persons: the InCHIANTI study. J Gerontol A Biol Sci Med Sci. 2004;59(3):242–8.CrossRefPubMed
35.
go back to reference Franceschi C, Capri M, Monti D, Giunta S, Olivieri F, Sevini F, et al. Inflammaging and anti-inflammaging: a systemic perspective on aging and longevity emerged from studies in humans. Mech Ageing Dev. 2007;128(1):92–105.CrossRefPubMed Franceschi C, Capri M, Monti D, Giunta S, Olivieri F, Sevini F, et al. Inflammaging and anti-inflammaging: a systemic perspective on aging and longevity emerged from studies in humans. Mech Ageing Dev. 2007;128(1):92–105.CrossRefPubMed
36.
go back to reference Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352(1):20–8.CrossRefPubMed Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352(1):20–8.CrossRefPubMed
37.
go back to reference Hansen KE, Hildebrand JP, Ferguson EE, Stein JH. Outcomes in 45 patients with statin-associated myopathy. Arch Intern Med. 2005;165(22):2671–6.CrossRefPubMed Hansen KE, Hildebrand JP, Ferguson EE, Stein JH. Outcomes in 45 patients with statin-associated myopathy. Arch Intern Med. 2005;165(22):2671–6.CrossRefPubMed
38.
go back to reference Rengo JL, Callahan DM, Savage PD, Ades PA, Toth MJ. Skeletal muscle ultrastructure and function in statin-tolerant individuals. Muscle Nerve. 2016;53(2):242–51.CrossRefPubMed Rengo JL, Callahan DM, Savage PD, Ades PA, Toth MJ. Skeletal muscle ultrastructure and function in statin-tolerant individuals. Muscle Nerve. 2016;53(2):242–51.CrossRefPubMed
39.
go back to reference Anderson GD. Sex and racial differences in pharmacological response: where is the evidence? Pharmacogenetics, pharmacokinetics, and pharmacodynamics. J Womens Health (Larchmt). 2005;14(1):19–29.CrossRef Anderson GD. Sex and racial differences in pharmacological response: where is the evidence? Pharmacogenetics, pharmacokinetics, and pharmacodynamics. J Womens Health (Larchmt). 2005;14(1):19–29.CrossRef
40.
go back to reference Mangoni AA, Jackson SH. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol. 2004;57(1):6–14.CrossRefPubMedPubMedCentral Mangoni AA, Jackson SH. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol. 2004;57(1):6–14.CrossRefPubMedPubMedCentral
41.
go back to reference DeGorter MK, Tirona RG, Schwarz UI, Choi YH, Dresser GK, Suskin N, et al. Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care. Circ Cardiovasc Genet. 2013;6(4):400–8.CrossRefPubMedPubMedCentral DeGorter MK, Tirona RG, Schwarz UI, Choi YH, Dresser GK, Suskin N, et al. Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care. Circ Cardiovasc Genet. 2013;6(4):400–8.CrossRefPubMedPubMedCentral
42.
go back to reference Schwartz JB, Verotta D. Population analyses of atorvastatin clearance in patients living in the community and in nursing homes. Clin Pharmacol Ther. 2009;86(5):497–502.CrossRefPubMed Schwartz JB, Verotta D. Population analyses of atorvastatin clearance in patients living in the community and in nursing homes. Clin Pharmacol Ther. 2009;86(5):497–502.CrossRefPubMed
44.
go back to reference Lowrie RLS, McConnachie A, Morrison J. A cluster randomised controlled trial of a pharmacist-led collaborative intervention to improve statin prescribing and attainment of cholesterol targets in primary care. PloS One. 2014;9:e113370.CrossRefPubMedPubMedCentral Lowrie RLS, McConnachie A, Morrison J. A cluster randomised controlled trial of a pharmacist-led collaborative intervention to improve statin prescribing and attainment of cholesterol targets in primary care. PloS One. 2014;9:e113370.CrossRefPubMedPubMedCentral
45.
go back to reference Simons LACE. Are high coronary risk patients missing out on lipid-lowering drugs in Australia? Med J Aust. 2014;201:213–6.CrossRefPubMed Simons LACE. Are high coronary risk patients missing out on lipid-lowering drugs in Australia? Med J Aust. 2014;201:213–6.CrossRefPubMed
46.
go back to reference Rowan CG, Brunelli SM, Munson J, Flory J, Reese PP, Hennessy S, et al. Clinical importance of the drug interaction between statins and CYP3A4 inhibitors: a retrospective cohort study in The Health Improvement Network. Pharmacoepidemiol Drug Saf. 2012;21(5):494–506.CrossRefPubMedPubMedCentral Rowan CG, Brunelli SM, Munson J, Flory J, Reese PP, Hennessy S, et al. Clinical importance of the drug interaction between statins and CYP3A4 inhibitors: a retrospective cohort study in The Health Improvement Network. Pharmacoepidemiol Drug Saf. 2012;21(5):494–506.CrossRefPubMedPubMedCentral
Metadata
Title
Associations Between Statin Use and Physical Function in Older Adults from The Netherlands and Australia: Longitudinal Aging Study Amsterdam and Australian Longitudinal Study on Women’s Health
Publication date
01-06-2016
Published in
Drugs & Aging / Issue 6/2016
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI
https://doi.org/10.1007/s40266-016-0370-5

Other articles of this Issue 6/2016

Drugs & Aging 6/2016 Go to the issue